Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Inclusion Criteria: * Postmenarcheal, premenopausal female aged 14 to 35 years (inclusive) * At risk for pregnancy (including heterosexual vaginal intercourse at least once a month and not sterilized). * No desire for pregnancy within 1 year following screening and is not intending to use any other form of contraception * Good physical and mental health * History of regular menstrual cycles prior to the use of any hormonal contraceptive. * Able and willing to adhere study procedures Exclusion Criteria: * Current known or expected pregnancy * History of subfertility or infertility * Less than 2 normal menstrual cycles following recent pregnancy of gestational age * Breastfeeding within 2 months of study drug start * Known HIV infection * Untreated gonorrhea, chlamydia, or trichomonas * abnormal PAP within timeline of standard of care guidelines * Unexplained/unresolved abnormal vaginal bleeding * Presence/history of VTE, ATE, transient ischemic attack, angina pectoris, or claudication * Higher risk for VTE * Uncontrolled or severe hypertension * Severe dyslipoproteinemia * History of migraine with aura or focal neurological symptoms * Diabetes mellitus (with either end-organ involvement or \>20 years duration) * Multiple cardiovascular risk factors * History of pancreatitis associated with severe hypertriglyceridemia * Presence/history of clinically significant liver disease * History of malabsorptive surgical procedures * History of malignancy in last 5 years * Presence/history of meningioma * Disease that may worsen under hormonal treatment * Presence/history of severe depression (unless currently stable and asymptomatic) * Known allergy/sensitivity to NOMAC-E2 * Drug or alcohol abuse/dependence in last 2 years * Clinically relevant abnormal lab result at screening * Expected use of other contraceptive medications or medications that induce liver enzymes during study * Used another investigational drug within 2 months of study drug start